Alzheimer's genetic how is it treated ?

Alzheimer's disease treatments represent worldwide huge challengers and are among the most important nowadays concerns. Alzheimer's disease treatments worldwide leaders will meet at the CTAD 2019 Congress in order to discuss new results, candidate therapeutics, and methodological issues. Alzheimer's disease symptoms and dementia treatment will be dealt with at the CTAD 2019 Congress. The CTAD 2019 Congress will provide the participants with new reports on the biomarkers from the clinical trial teams. The future of clinical trials may lie in revisiting all drugs known to be safe and evaluate their relevance in AD treatment. The importance of non-pharmaceutical trials and that anti-amyloid treatment for AD was shown at the 2018 CTAD Congress. Tau Biomarkers was proved to be one of the therapeutics combination as shown in the phase 43 clinical trials results. Studies on the early stage symptoms will be presented at the 2019 CTAD Congress by the clinical teams. New examples of trials will be highlighted in the 2019 CTAD Congress. Overall, the aim of the conference is to overcome the hurdles and speed the development of effective treatments. The JPAD Journal of Prevention of Alzheimer's Disease will publish reviews, original research articles and short reports to improve our knowledge in the field of Alzheimer prevention including : neurosciences, biomarkers, imaging, epidemiology, public health, physical cognitive exercise, nutrition, risk and protective factors, drug development, trials design, and health economic outcomes.